Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026)
Puma Biotechnology (PBYI) recorded Income from Continuing Operations of $8.25 million in Q2 2026, up 33.7% from $6.17 million a year earlier.
Powered by 
Analysis
Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
On a TTM basis, Puma Biotechnology's Income from Continuing Operations came in at $31.17 million as of Jun 30, 2026, down 25.8% year-over-year; for FY2025, it was $35.78 million, up 48.5% from FY2024.
- Across earlier years, Income from Continuing Operations came in at $24.1 million in FY2024 (+11.6%), $21.59 million in FY2023, $2,000 in FY2022 and -$29.13 million in FY2021.
- Quarterly Income from Continuing Operations has ranged from -$44.67 million in Q3 2021 to $20.32 million in Q3 2024 over the past five years.
- On a year-over-year basis, Income from Continuing Operations rose in three of the last five quarters, with growth averaging 53.9%.
- Per Business Quant, the preceding three quarters came in at -$3.43 million (Q1 2026), $17.11 million (Q4 2025) and $9.24 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.07 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 4.80 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 3.86 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.25 Bn |
| 10 | Puma Biotechnology | 420.82 Mn | 19.27 Mn | 39.86 Mn | 6.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 6.39 Mn |
| Jun 30, 2026 | 8.30 Mn |
| Mar 31, 2026 | -3.10 Mn |
| Dec 31, 2025 | 17.53 Mn |
| Sep 30, 2025 | 9.64 Mn |
| Jun 30, 2025 | 6.48 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Dec 31, 2024 | 14.02 Mn |
| Sep 30, 2024 | 20.32 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | 12.27 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | -5.61 Mn |
| Sep 30, 2022 | -360,000.00 |
| Jun 30, 2022 | 9.37 Mn |
| Mar 31, 2022 | -3.40 Mn |
| Dec 31, 2021 | 4.22 Mn |
API Access
Puma Biotechnology Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=PBYI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "PBYI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=PBYI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();